Compare Amgen, Inc. (AMGN) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Nu Holdings Ltd — how do they compare? Amgen, Inc. trades at $362.02 (market cap $196.12B), while Nu Holdings Ltd trades at $13.73 (market cap $66.47B). The key difference: Amgen, Inc. is far larger — about 3× Nu Holdings Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| AMGN | NU | |
|---|---|---|
Market Cap | $196.12B | $66.47B |
Sector | Health | Financials |
52-Week High | $388.16 | $18.76 |
52-Week Low | $271.18 | $11.60 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NU Holdings Ltd. (NU) trades at $13.76, up 0.66% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Revenue grew to $10.63B in 2025 with net income of $2.87B, and the company recently secured authorization for its Mexican banking operations, expanding its Latin American footprint. Analyst consensus is a Buy with a $14.98 price target, though recent quarterly EPS results have missed expectations.
The outlook for NU remains positive due to robust revenue growth and expansion potential, but risks include currency headwinds and competitive pressures. The stock's current valuation at a P/E of 21.22 and P/S of 5.67 reflects its growth trajectory, yet investors should monitor execution risks in new markets and credit portfolio performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
